Novartis’ Cosentyx Beginning to Plateau in Psoriatic Arthritis, as US Rheumatologists Prepare for an Influx of Non-TNF Agents, Such as BMS’ Orencia, Pfizer’s Xeljanz, and Lilly’s IL-17, Taltz

Despite an increasing user base, Cosentyx share has remained unchanged over the past six months, according to recently released data from Spherix Global Insights Download Report Overview EXTON, Pa., Aug. 15, 2017 /PRNewswire/ — In the most recent quarterly update…

Continue Reading

Likely Delay for Janssen’s Sirukumab Sets up Head to Head Battle Between Roche/Genentech’s Actemra and Sanofi/Regeneron’s Kevzara in the US Rheumatoid Arthritis Market

Despite Kevzara’s aggressive pricing play, early launch metrics of the newest IL-6 inhibitor, indicate conservative uptake, according to Spherix Global Insight’s most recent quarterly update Download Report Overview EXTON, Pa., Aug. 9, 2017 /PRNewswire/ — Following an unfavorable recommendation from…

Continue Reading